



KERALA MEDICAL SERVICES CORPORATION LTD.,
(Dept. of Health & Family Welfare, Govt. of Kerala)
Thycaud P.O., Thiruvananthapuram-14
Tele Fax No : 0471-2945647, 0471-2945600
Email id : edrugs.kmscl@kerala.gov.in
CIN : U24233KL2007SGC021616

Essential Drugs Division
No. KMSCL/ED/40/2023

www.kmscl.kerala.gov.in
Date : 30.04.2024

NOTICE

(Anti Cancer Drugs)

Sub :- KMSCL – E-tender for the Procurement of Anti Cancer Drugs for the year 2024-25 – Technical Bid Evaluation – Defects noticed and status– Published – reg.

Ref :- 1. E-tender No. KMSCL/ED/ACD/RC/2024/001 Dated 05.01.2024.
2. Amendment notice no. KMSCL/ED/40/2023 dated 20.01.2024.

Technical bids submitted in response to the e-tender referred above for the procurement of Anticancer Drugs for the year 2024-25 were opened on 01.02.2024 and scrutinized. The status is published below.

All the bidders are directed to verify the details of their offered items in the notice published.

The complaints/suggestions/representations, if any, on this notice shall be submitted to the Tender Inviting Authority in writing on or before **5 pm on 10.05.2024**.

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
Bid No. 1		M/s. MSN Laboratories Private Limited, Telangana			
1.	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	1. Notary attested copy of Market Standing Certificate not submitted for the following; D24170C- ABIRATERONE ACETATE TAB IP, 250 mg D24294C- FERRIC CARBOXYMALTOSE INJ, 1gm/20 ml, Vial D24207C- PAZOPANIB TAB 400 mg D24242C NILOTINIB CAP 150 mg D24201C NILOTINIB CAP 200 mg
2.	D24304C	CABOZANTINIB TAB	20 mg	1 no	
3.	D24294C	FERRIC CARBOXYMALTOSE INJ	1gm/20 ml	Vial	
4.	D24207C	PAZOPANIB TAB	400 mg	1 no	
5.	D24242C	NILOTINIB CAP	150 mg	1 no	
6.	D24201C	NILOTINIB CAP	200 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
					<p>200 mg</p> <p>2. Notary attested copy of Market Standing Certificate not submitted as per clause 5.2.5.6 for D24304C-CABOZANTINIB TAB 20 mg</p> <p>3. Notary attested copy of WHO GMP Certificate for the manufacturing units bearing license number 5/MN/TS/2014/F/G & 38/MD/AP/2007/F/CC not submitted.</p> <p>4. Notary attested details of 3 batches not furnished in the Performance Statement (Annexure-IV) submitted for the following. D24304C-CABOZANTINIB TAB 20 mg</p> <p>D24294C- FERRIC CARBOXYMALTOSE INJ, 1gm/20 ml, Vial</p> <p>D24242C NILOTINIB CAP 150 mg</p> <p>D24201C NILOTINIB CAP 200 mg</p>
Bid No. 2		M/s. Novartis Healthcare Pvt Ltd, Maharashtra			
1.	D24262C	CERITINIB CAP	150 mg	1 no	<p>1. Notary attested copy of previous import license issued three years prior to the date of notification of tender is not submitted for the quoted items.</p> <p>2. Notary attested copy of Market standing certificate submitted for D24262C CERITINIB CAP 150 mg is</p>

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
2.	D24242C	NILOTINIB CAP	150 mg	1no	in the name of M/s. Sandoz Pvt Ltd instead of M/s. Novartis Healthcare Pvt Ltd. Clarification is to be submitted.
3.	D24201C	NILOTINIB CAP	200 mg	1no	3. Notary attested copy of Valid Sale License issued by the Licensing Authority for sale of D24262C CERITINIB CAP 150 mg imported by the bidder and also its Non conviction certificate not submitted.
Bid No. 3		M/s. Intas Pharmaceuticals Limited, Ahmedabad			
1.	D24060C	BEVACIZUMAB INJ	100 mg	Vial	<p>1. Product Permit and Market Standing Certificate submitted is for (PEGYLATED LIPOSOMAL) instead of tendered specification for D24090C DOXORUBICIN LIPOSOMAL INJ 20mg Vial.</p> <p>2. D24066C-CAPECITABINE TAB IP 500 mg is offered from the manufacturing unit bearing license no. G/1883 in the Bid offer form (Annexure II) and Product permit submitted. Market standing certificate against the aforesaid manufacturing license not submitted.</p>
2.	D24298C	BEVACIZUMAB INJ	400 mg	Vial	
3.	D24061C	BICALUTAMIDE TAB IP	50 mg	1 no	
4.	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
5.	D24067C	CARBOPLATIN INJ IP	150 mg	Vial	
6.	D24068C	CARBOPLATIN INJ IP	450 mg	Vial	
7.	D24077C	CYTARABINE INJ IP/BP	100 mg	Vial	
8.	D24188C	DENOSUMAB INJ	120 mg	Vial	
9.	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
10.	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
11.	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
12.	D24228C	FILGRASTIM INJ IP	300 mcg	PFS	
13.	D24105C	GEMCITABINE INJ IP	1 gm	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status	
14.	D24104C	GEMCITABINE INJ IP	200 mg	Vial		
15.	D24120C	LETROZOLE TAB IP/USP	2.5 mg	1 no		
16.	D24255C	PACLITAXEL NANOPARTICLE INJ	100 mg	Vial		
17.	D24140C	PEGFILGRASTIM INJ	6 mg	Vial/PFS		
18.	D24090C	DOXORUBICIN LIPOSOMAL INJ	20 mg	Vial		
19.	D24091C	DOXORUBICIN (PEGYLATED LIPOSOMAL) INJ	50 mg	Vial		
20.	D24145C	RITUXIMAB INJ	100 mg	Vial		
21.	D24146C	RITUXIMAB INJ	500 mg	Vial		
22.	D24269C	TRASTUZUMAB INJ	150 mg	Vial		
23.	D24156C	TRASTUZUMAB INJ	440 mg	Vial		
Bid No. 4		M/s. Shilpa Medicare Limited, Mumbai				
1.	D24141C	PEMETREXED INJ IP	100 mg	Vial		1. The firm had offered the items in the Bid Offer Form from License no. L/19/2056/MNB, Original Manufacturing License, Product Permit, WHO GMP Certificate and Non Conviction Certificate submitted is for license no. L/18/2055/MNB & L/18/2056/MB.
2.	D24142C	PEMETREXED INJ IP	500 mg	Vial		
Bid No. 5		M/s. Samarth Life Sciences Pvt. Ltd.				
1	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	1) Tendered Strength and Unit not mentioned in the Product Permit & Market Standing Certificate submitted for the following;	
2	D24058C	ANASTRAZOLE TAB IP	1 mg	1 no		
3	D24061C	BICALUTAMIDE TAB IP	50 mg	1 no		

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
4	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	D24064C- LEUCOVORIN CALCIUM INJ IP 15 mg Amp D24065C- LEUCOVORIN CALCIUM INJ IP 50 mg Vial 2) Tendered Monograph "IP" not mentioned in the Product Permit & Market Standing Certificate submitted for D24133C OXALIPLATIN INJ IP 50 mg Vial D24134C OXALIPLATIN INJ IP 100 mg Vial 3) Notary attested copy of Non-conviction Certificate submitted does not bear the seal of the Drugs Controller.
5	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
6	D24103C	GEFITINIB TAB IP	250 mg	1 no	
7	D24118C	LAPATINIB TAB IP	250 mg	1no	
8	D24160C	ZOLEDRONIC ACID INJ IP	4 mg	Vial	
9	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
10	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
11	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
12	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
13	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
14	D24164C	IMATINIB TAB IP	400 mg	1 no	
15	D24064C	LEUCOVORIN CALCIUM INJ IP	15 mg	Amp	
16	D24065C	LEUCOVORIN CALCIUM INJ IP	50 mg	Vial	
17	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
18	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
19	D24141C	PEMETREXED INJ IP	100 mg	Vial	
20	D24142C	PEMETREXED INJ IP	500 mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
21	D24152C	TEMOZOLOMIDE CAP IP	100 mg	1 no	
Bid No. 6		M/s. Khandelwal Laboratories Pvt Ltd, Mumbai			
1	D24058C	ANASTRAZOLE TAB IP	1mg	1 no	<p>1) Tendered monograph (IP) not mentioned in the Product Permit & Market Standing Certificate submitted for the following;</p> <p>D24092C EPIRUBICIN INJ IP 10mg Vial D24093C EPIRUBICIN INJ IP 50mg Vial</p> <p>2) For D24062C - BLEOMYCIN INJ IP, 15 units, Vial, the unit mentioned in the bid offer form is 15mg instead of 15 units.</p> <p>3) Notary attested copy of Market Standing Certificate to prove three year market standing issued by the licensing authority is not submitted for the following;</p> <p>D24115C - IRINOTECAN INJ IP, 40 mg, Vial D24116C - IRINOTECAN INJ IP, 100 mg, Vial</p>
2	D24062C	BLEOMYCIN INJ IP	15 units	Vial	
3	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
4	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
5	D24077C	CYTARABINE INJ IP/BP	100 mg	Vial	
6	D24096C	ETOPOSIDE CAP IP	50 mg	1 no	
7	D24097C	ETOPOSIDE INJ IP	100 mg	Vial	
8	D24103C	GEFITINIB TAB IP	250 mg	1 no	
9	D24120C	LETROZOLE TAB IP/USP	2.5 mg	1 no	
10	D24150C	TAMOXIFEN TAB IP	20 mg	1 no	
11	D24160C	ZOLEDRONIC ACID INJ IP	4 mg	Vial	
12	D24067C	CARBOPLATIN INJ IP	150 mg	Vial	
13	D24068C	CARBOPLATIN INJ IP	450 mg	Vial	
14	D24071C	CISPLATIN INJ IP	10 mg	Vial	
15	D24072C	CISPLATIN INJ IP	50 mg	Vial	
16	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
17	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
18	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
19	D24087C	DOXORUBICIN INJ (LYOPHILISED) IP	10mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
20	D24088C	DOXORUBICIN INJ (LYOPHILISED) IP	50 mg	Vial	
21	D24092C	EPIRUBICIN INJ IP	10 mg	Vial	
22	D24093C	EPIRUBICIN INJ IP	50 mg	Vial	
23	D24094C	ERLOTINIB TAB IP	100 mg	1 no	
24	D24095C	ERLOTINIB TAB IP	150 mg	1 no	
25	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
26	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
27	D24115C	IRINOTECAN INJ IP	40 mg	Vial	
28	D24116C	IRINOTECAN INJ IP	100 mg	Vial	
29	D24127C	METHOTREXATE INJ IP	50 mg	Vial	
30	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
31	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
32	D24136C	PACLITAXEL INJ IP	30 mg	Vial	
33	D24137C	PACLITAXEL INJ IP WITH CODON SET	100 mg	Vial	
34	D24138C	PACLITAXEL INJ IP WITH CODON SET	260 mg	Vial	
35	D24141C	PEMETREXED INJ IP	100 mg	Vial	
36	D24142C	PEMETREXED INJ IP	500 mg	Vial	
37	D24152C	TEMOZOLOMIDE CAP IP	100 mg	1 no	
38	D24153C	TEMOZOLOMIDE CAP IP	250 mg	1 no	
Bid No. 7		M/s. Novartis India Ltd, Maharashtra			
1	D24295C	OCTREOTIDE INJ	30 mg	Vial / Amp /PFS	1) Tendered Specification "Unit" not mentioned in the Bid Offer

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
2	D24296C	OCTREOTIDE INJ	20 mg	Vial / PFS	Form (Annexure-II) submitted for the following; D24296C- OCTREOTIDE INJ 20 mg, Vial/PFS D24295C- OCTREOTIDE INJ 30 mg, Vial/Amp/PFS.
Bid No. 8		M/s. Cipla Ltd, Mumbai.			
1.	D24066C	CAPECITABINE TAB IP	500 mg	1 no	Submitted the required documents.
2.	D24103C	GEFITINIB TAB IP	250 mg	1 no	
3.	D24120C	LETROZOLE TAB IP/USP	2.5 mg	1 no	
4.	D24147C	SORAFENIB TOSYLATE TAB IP	200 mg	1 no	
Bid No. 9		M/s. Reliance Life Sciences. Pvt. Ltd, Mumbai.			
1	D24066C	CAPECITABINE TAB IP	500 mg	1 no	1) The following products is offered from the manufacturing unit bearing license no. KD/681 in the Bid offer form (Annexure II) submitted, but the Product Permit submitted is from the manufacturing unit bearing license No. KD/476 . D24141C - PEMETREXED INJ IP 100mg, Vial D24142C - PEMETREXED INJ IP 500mg, Vial 2) Notary attested copy of Original Manufacturing License bearing License no.
2	D24228C	FILGRASTIM INJ IP	300 mcg	PFS	
3	D24140C	PEGFILGRASTIM INJ	6 mg	Vial/PFS	
4	D24060C	BEVACIZUMAB INJ	100 mg	Vial	
5	D24298C	BEVACIZUMAB INJ	400 mg	Vial	
6	D24119C	LENALIDOMIDE CAP	10 mg	1 no	
7	D24252C	LENALIDOMIDE CAP	25 mg	1 no	
8	D24163C	LENALIDOMIDE CAP	5 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
9	D24141C	PEMETREXED INJ IP	100 mg	Vial	KD/681 not submitted. 3) Tended Monograph (IP) not mentioned in the Market Standing Certificate submitted for the following; D24141C- PEMETREXED INJ IP 100mg, Vial D24142C- PEMETREXED INJ IP 500mg, Vial
10	D24142C	PEMETREXED INJ IP	500 mg	Vial	
11	D24145C	RITUXIMAB INJ	100 mg	Vial	
12	D24146C	RITUXIMAB INJ	500mg	Vial	
13	D24156C	TRASTUZUMAB INJ	440 mg	Vial	
14	D24269C	TRASTUZUMAB INJ	150 mg	Vial	
Bid No. 10		M/s. JODAS EXPOIM PVT LTD, Telangana			
1	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	1) Tended Monograph (IP) not mentioned in the Product permit submitted for D24170C ABIRATERONE ACETATE TAB IP 250 mg
2	D24058C	ANASTRAZOLE TAB IP	1mg	1 no	
3	D24059C	BENDAMUSTINE INJ IP	100mg	Vial	
4.	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	2) Notary attested copy of Product Permit and Market Standing not submitted for D24090C- DOXORUBICIN LIPOSOMAL INJ 20 mg Vial
5.	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
6.	D24090C	DOXORUBICIN LIPOSOMAL INJ	20 mg	Vial	3) Notary attested copy of Product Permit and Market Standing submitted is for "USP" Instead of tendered specification (IP) for the following D24133C-OXALIPLATIN INJ IP 50 mg Vial D24134C-OXALIPLATIN INJ IP 100 mg Vial
7.	D24102C	FULVESTRANT INJ	250 mg	Vial/PFS	
8.	D24120C	LETROZOLE TAB IP/USP	2.5 mg	1 no	
9.	D24144C	PROTEIN BOUND PACLITAXEL INJ	100 mg	Vial	
10.	D24147C	SORAFENIB TOSYLATE TAB IP	200 mg	1 no	
11.	D24216C	SUNITINIB CAP	12.5 mg	1 no	
12.	D24071C	CISPLATIN INJ IP	10 mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
13.	D24072C	CISPLATIN INJ IP	50 mg	Vial	<p>4) Since the product permit for the following items is issued on 2023, it is noted that the product is not having 3 year market standing.</p> <p>D24063C BORTEZOMIB INJ IP 2 mg Vial</p> <p>D24102C FULVESTANT INJ 250 mg Vial/PFS</p> <p>D24147C-SORAFENIB TOSYLATE TAB IP 200 mg</p> <p>D24120C LETROZOLE TAB IP/USP 2.5 mg</p> <p>D24141C PEMETREXED INJ IP 100 mg Vial</p> <p>D24142C PEMETREXED INJ IP 500 mg Vial</p> <p>Clarification to be submitted</p> <p>5) Tendered Monograph (IP) not mentioned in the Market Standing Certificate submitted for the following</p> <p>D24059C-BENDAMUSTINE INJ IP 100mg Vial</p> <p>D24105C GEMCITABINE INJ IP 1 gm Vial</p> <p>6) Since the product permit for D24144C- PROTEIN BOUND PACLITAXEL INJ 100 mg Vial is issued on 2021, it is noted that the product is not having 3 year market standing.</p> <p>Clarification to be submitted</p> <p>7) The details of License no: 35/SDP/TS/2016/F/G is not</p>
14.	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
15.	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
16	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
17	D24087C	DOXORUBICIN INJ (LYOPHILISED) IP	10 mg	Vial	
18	D24088C	DOXORUBICIN INJ (LYOPHILISED) IP	50 mg	Vial	
19	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
20	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
21	D24165C	IMATINIB TAB IP	100 mg	1 no	
22	D24164C	IMATINIB TAB IP	400 mg	1 No	
23	D24115C	IRINOTECAN INJ IP	40 mg	Vial	
24	D24116C	IRINOTECAN INJ IP	100 mg	Vial	
25	D24119C	LENALIDOMIDE CAP	10 mg	1 no	
26	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
27	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
28	D24136C	PACLITAXEL INJ IP	30 mg	Vial	
29	D24141C	PEMETREXED INJ IP	100 mg	Vial	
30	D24142C	PEMETREXED INJ IP	500 mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
					mentioned in the Annexure VIII (details of Bidder and Manufacturing units) submitted.
Bid No. 11		M/s. Fresenius Kabi Oncology Ltd, Haryana			
1.	D24059C	BENDAMUSTINE INJ IP	100 mg	Vial	<p>1) Annual Turn Over Statement submitted is not attested by Notary Public.</p> <p>2) Tendered Monograph (IP) not mentioned in the Product Permit and Market standing certificate submitted for the following;</p> <p>D24104C - GEMCITABINE INJ IP, 200 mg, vial D24105C - GEMCITABINE INJ IP, 1 gm, vial</p>
2.	D24255C	PACLITAXEL NANOPARTICLE INJ	100 mg	Vial	
3.	D24067C	CARBOPLATIN INJ IP	150 mg	Vial	
4.	D24068C	CARBOPLATIN INJ IP	450 mg	Vial	
5.	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
6.	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
7.	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
8.	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
9.	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
10.	D24115C	IRINOTECAN INJ IP	40 mg	Vial	
11.	D24116C	IRINOTECAN INJ IP	100 mg	Vial	
12.	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
13.	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
14.	D24136C	PACLITAXEL INJ IP	30 mg	Vial	
15.	D24137C	PACLITAXEL INJ IP WITH CODON SET	100 mg	Vial	
16.	D24138C	PACLITAXEL INJ IP WITH CODON SET	260 mg	Vial	
Bid No. 12		M/s. Beta Drugs Limited, Himachal Pradesh			
1.	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	1) Tendered monograph (IP) not mentioned in the Product

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
2.	D24059C	BENDAMUSTINE INJ IP	100 mg	Vial	Permit submitted for D24160C -ZOLEDRONIC ACID INJ IP, 4 mg, Vial 2) Tendered monograph (IP) not mentioned in the Market Standing Certificate submitted for D24059C BENDAMUSTINE INJ IP, 100 mg, Vial. 3) Notary attested copy of Market Standing Certificate submitted is for the Brand Name for the following Items, and also the tendered monograph (IP) not mentioned in Market Standing Certificate Submitted. D24136C - PACLITAXEL INJ IP, 30mg D24137C - PACLITAXEL INJ IP WITH CODON SET, 100mg D24138C - PACLITAXEL INJ IP WITH CODON SET, 260mg
3.	D24061C	BICALUTAMIDE TAB IP	50 mg	1 no	
4.	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
5	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
6	D24103C	GEFITINIB TAB IP	250 mg	1 no	
7	D24117C	L.ASPARAGINASE INJ	5000 iu	Vial	
8	D24144C	PROTEIN BOUND PACLITAXEL INJ	100 mg	Vial	
9	D24160C	ZOLEDRONIC ACID INJ IP	4 mg	Vial	
10	D24067C	CARBOPLATIN INJ IP	150 mg	Vial	
11	D24068C	CARBOPLATIN INJ IP	450 mg	Vial	
12	D24071C	CISPLATIN INJ IP	10 mg	Vial	
13	D24072C	CISPLATIN INJ IP	50 mg	Vial	
14	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
15	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
16	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
17	D24087C	DOXORUBICIN INJ (LYOPHILISED) IP	10 mg	Vial	
18	D24088C	DOXORUBICIN INJ (LYOPHILISED) IP	50 mg	Vial	
19	D24094C	ERLOTINIB TAB IP	100 mg	1 no	
20	D24095C	ERLOTINIB TAB IP	150 mg	1 no	
21	D24092C	EPIRUBICIN INJ IP	10 mg	Vial	
22	D24093C	EPIRUBICIN INJ IP	50 mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status	
23	D24104C	GEMCITABINE INJ IP	200 mg	Vial		
24	D24105C	GEMCITABINE INJ IP	1gm	Vial		
25	D24165C	IMATINIB TAB IP	100 mg	1 no		
26	D24164C	IMATINIB TAB IP	400 mg	1 no		
27	D24119C	LENALIDOMIDE CAP	10 mg	1 no		
28	D24252C	LENALIDOMIDE CAP	25 mg	1no		
29	D24133C	OXALIPLATIN INJ IP	50 mg	Vial		
30	D24134C	OXALIPLATIN INJ IP	100 mg	Vial		
31	D24136C	PACLITAXEL INJ IP	30 mg	Vial		
32	D24137C	PACLITAXEL INJ IP WITH CODON SET	100 mg	Vial		
33	D24138C	PACLITAXEL INJ IP WITH CODON SET	260 mg	Vial		
34	D24141C	PEMETREXED INJ IP	100 mg	Vial		
35	D24142C	PEMETREXED INJ IP	500 mg	Vial		
36	D24152C	TEMOZOLOMIDE CAP IP	100 mg	1 no		
37	D24153C	TEMOZOLOMIDE CAP IP	250 mg	1 no		
Bid No. 13		M/s. Adley Formulation Private Limited, Haryana				
1.	D24096C	ETOPOSIDE CAP IP	50 mg	1 no		1) Tendered monograph IP not mentioned in the Product Permit submitted for the following; D24115C - IRINOTECAN INJ IP , 40 mg, Vial D24116C - IRINOTECAN INJ IP , 100 mg, Vial
2.	D24097C	ETOPOSIDE INJ IP	100 mg	Vial		
3.	D24102C	FULVESTRANT INJ	250 mg	Vial/PFS		
4.	D24118C	LAPATINIB TAB IP	250 mg	1no		

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
5.	D24147C	SORAFENIB TOSYLATE TAB IP	200 mg	1 no	2) Tendered unit- Vial/PFS not specified in the product permit and Market Standing Certificate submitted for D24102C - FULVESTRANT INJ 250 mg, Vial/PFS .
6.	D24154C	THALIDOMIDE CAP USP	100 mg	1 no	
7	D24115C	IRINOTECAN INJ IP	40 mg	Vial	
8	D24116C	IRINOTECAN INJ IP	100 mg	Vial	3) Tendered monograph (USP) not mentioned in the product permit submitted for D24154C - THALIDOMIDE CAP USP , 100 mg. 4) Tendered monograph IP not mentioned in the Market Standing Certificate submitted for D24097C -ETOPOSIDE INJ IP , 100 mg, Vial. 5) Notary attested copy of Market standing certificate not submitted for D24115C - IRINOTECAN INJ IP 40 mg Vial D24116C - IRINOTECAN INJ IP 100 mg Vial
Bid No. 14		M/s. ZYDUS LIFESCIENCES LIMITED, Gujarat			
1.	D24058C	ANASTRAZOLE TAB IP	1mg	1 no	1) The details of drugs quoted are different in the “pdf format” and “excel format” of the Bid Offer Form (Annexure II) submitted. If any discrepancy found with excel format, details submitted in the PDF format will prevail as per clause 6.15.3 of the tender document. 2) Notary attested copy of renewal/retention/current validity certificate of the manufacturing units bearing
2.	D24167C	AZATHIOPRINE TAB IP	50 mg	1 no	
3.	D24228C	FILGRASTIM INJ IP	300 mcg	PFS	
4.	D24140C	PEGFILGRASTIM INJ.	6 mg	Vial/PFS	
5.	D24060C	BEVACIZUMAB INJ	100 mg	Vial	
6.	D24298C	BEVACIZUMAB INJ	400 mg	Vial	
7.	D24156C	TRASTUZUMAB INJ	440 Mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
8	D24269C	TRASTUZUMAB INJ	150 mg	Vial	license no. M/816/2017 not submitted. 3) Tendered monograph IP not mentioned in the Product Permit and Market Standing Certificate submitted for D24228C - FILGRASTIM INJ IP , 300 mcg, PFS. 4) Notary attested copy of WHO-GMP certificate not submitted for the manufacturing unit bearing license number M/816/2017 .
Bid No. 15		M/s. ADMAC LIFESCIENCES, Haryana			
1.	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	1) Tendered monograph (IP) not mentioned in the Product Permit and Market Standing Certificate submitted for the following D24092C-EPIRUBICIN INJ IP , 10 mg, Vial D24093C-EPIRUBICIN INJ IP , 50 mg, Vial 2) Notary attested copy of Market Standing Certificate issued by the licensing authority to prove 3 year Market Standing not submitted for the following; D24077C- CYTARABINE INJ IP/BP 100mg Vial D24242C-NILOTINIB CAP, 150 mg D24201C-NILOTINIB CAP, 200 mg, 1no 3) In the case of New Drugs for which patent period has been expired during last two
2	D24172C	AFATINIB TAB	30 mg	1 no	
3	D24058C	ANASTRAZOLE TAB IP	1 mg	1 no	
4	D24177C	AXITINIB TAB	5 mg	1 no	
5	D24061C	BICALUTAMIDE TAB IP	50 mg	1 no	
6	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
7	D24066C	CAPECITABINE TAB IP	500 mg	1 no	
8	D24077C	CYTARABINE INJ IP/BP	100 mg	Vial	
9	D24078C	DACARBAZINE INJ IP/USP	200 mg	Vial	
10	D24096C	ETOPOSIDE CAP IP	50 mg	1 no	
11	D24097C	ETOPOSIDE INJ IP	100 mg	Vial	
12	D24103C	GEFITINIB TAB IP	250 mg	1 no	
13	D24117C	L.ASPARAGINASE INJ	5000 iu	Vial	
14	D24274C	LENVATINIB CAP	4 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
15	D24120C	LETROZOLE TAB IP/USP	2.5mg	1 no	<p>financial years, the bidder should submit the approval from the respective DCGI or from State Drugs control office to the effect exemption for the following items.</p> <p>D24172C- AFATINIB TAB 30 mg</p> <p>D24177C- AXITINIB TAB 5 mg</p> <p>D24274C- LENVATINIB CAP 4 mg</p> <p>D24216C- SUNITINIB CAP 12.5 mg</p> <p>D24207C- PAZOPANIB TAB 400 mg</p> <p>D24079C- DASATINIB TAB 20 mg</p> <p>D24080C- DASATINIB TAB 50 mg</p> <p>4) Notary attested copy of Performance Statement in Annexure IV not submitted for the following;</p> <p>D24242C-NILOTINIB CAP, 150 mg</p> <p>D24201C-NILOTINIB CAP, 200 mg</p>
16	D24207C	PAZOPANIB TAB	400 mg	1no	
17	D24147C	SORAFENIB TOSYLATE TAB IP	200 mg	1 no	
18	D24216C	SUNITINIB CAP	12.5 mg	1 no	
19	D24150C	TAMOXIFEN TAB IP	20 mg	1 no	
20	D24154C	THALIDOMIDE CAP USP	100 mg	1 no	
21	D24160C	ZOLEDRONIC ACID INJ IP	4 mg	Vial	
22	D24067C	CARBOPLATIN INJ IP	150 mg	Vial	
23	D24068C	CARBOPLATIN INJ IP	450 mg	Vial	
24	D24071C	CISPLATIN INJ IP	10 mg	Vial	
25	D24072C	CISPLATIN INJ IP	50 mg	Vial	
26	D24079C	DASATINIB TAB	20 mg	1no	
27	D24080C	DASATINIB TAB	50 mg	1 no	
28	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
29	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
30	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
31	D24087C	DOXORUBICIN INJ (LYOPHILISED) IP	10 mg	Vial	
32	D24088C	DOXORUBICIN INJ (LYOPHILISED) IP	50 mg	Vial	
33	D24092C	EPIRUBICIN INJ IP	10 mg	Vial	
34	D24093C	EPIRUBICIN INJ IP	50 mg	Vial	
35	D24094C	ERLOTINIB TAB IP	100 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
36	D24095C	ERLOTINIB TAB IP	150 mg	1 no	
37	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
38	D24105C	GEMCITABINE INJ IP	1gm	Vial	
39	D24165C	IMATINIB TAB IP	100 mg	1 no	
40	D24164C	IMATINIB TAB IP	400 mg	1 no	
41	D24119C	LENALIDOMIDE CAP	10 mg	1 no	
42	D24252C	LENALIDOMIDE CAP	25 mg	1no	
43	D24163C	LENALIDOMIDE CAP	5 mg	1 no	
44	D24065C	LEUCOVORIN CALCIUM INJ IP	50 mg	Vial	
45	D24127C	METHOTREXATE INJ IP	50 mg	Vial	
46	D24242C	NILOTINIB CAP	150 mg	1no	
47	D24201C	NILOTINIB CAP	200 mg	1no	
48	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
49	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
50	D24136C	PACLITAXEL INJ IP	30 mg	Vial	
51	D24137C	PACLITAXEL INJ IP WITH CODON SET	100 mg	Vial	
52	D24138C	PACLITAXEL INJ IP WITH CODON SET	260 mg	Vial	
53	D24141C	PEMETREXED INJ IP	100 mg	Vial	
54	D24142C	PEMETREXED INJ IP	500 mg	Vial	
55	D24152C	TEMOZOLOMIDE CAP IP	100 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
56	D24153C	TEMOZOLOMIDE CAP IP	250 mg	1 no	
Bid No. 16		M/s. Bharat Serums And Vaccines Limited, Mumbai			
1.	D24294C	FERRIC CARBOXYMALTOSE INJ	1gm/20ml	Vial	<p>1. Notary attested copy of Market Standing Certificate issued by the licensing authority to prove three year market standing is not submitted for D24294C – FERRIC CARBOXYMALTOSE INJ, 1gm/ 20ml, Vial</p> <p>2. Details of three batches not furnished in the performance statement (Annexure - IV) submitted for FERRIC CARBOXYMALTOSE INJ, 1gm/ 20ml, Vial</p>
2	D24121C	LEUPROLIDE ACETATE INJ	3.75mg	Vial	
3	D24122C	LEUPROLIDE ACETATE INJ	11.25mg	Vial	
4	D24250C	LEUPROLIDE ACETATE INJ	22.5mg	Vial	
Bid No. 17		M/s. Medicamen Biotech Limited, New Delhi			
1.	D24170C	ABIRATERONE ACETATE TAB IP	250 mg	1 no	<p>1) It is noted that product permit for the following items is issued on 2020 & 2021 respectively, and the market standing certificate submitted also shows that the products are having 3 year marketing.</p> <p>But as per the performance statement (Anx-IV) submitted, it is seen that the products have not been marketed</p>
2.	D24063C	BORTEZOMIB INJ IP	2mg	Vial	
3	D24274C	LENVATINIB CAP	4 MG	1 no	
4	D24207C	PAZOPANIB TAB	400 mg	1no	
5	D24094C	ERLOTINIB TAB IP	100 mg	1 no	
6	D24095C	ERLOTINIB TAB IP	150 mg	1 no	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
7	D24152C	TEMOZOLOMIDE CAP IP	100 mg	1 no	during the financial year 2020-21. Clarification is to be submitted
8	D24153C	TEMOZOLOMIDE CAP IP	250 mg	1 no	D24152C-TEMOZOLOMIDE CAP IP, 100 mg D24153C- TEMOZOLOMIDE CAP IP, 250 mg D24063C-BORTEZOMIB INJ IP 2mg Vial D24274C- LENVATINIB CAP 4 MG
Bid No. 18		M/s. GLS Pharma Limited, Telangana			
1.	D24059C	BENDAMUSTINE INJ IP	100 mg	Vial	1. Details of 3 batches not furnished in the Performance Statement (Annexure-IV) submitted for D24101C – FLUDARABINE PHOSPHATE INJ IP/ USP 50 mg Vial
2.	D24062C	BLEOMYCIN INJ IP	15 Units	Vial	
3	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
4	D24077C	CYTARABINE INJ IP/BP	100 mg	Vial	
5	D24161C	DEXAMETHASONE TAB IP	8 mg	1 no	
6	D24169C	DEXAMETHASONE TAB IP	4 mg	1 no	
7	D24090C	DOXORUBICIN LIPOSOMAL INJ	20 mg	Vial	
8	D24101C	FLUDARABINE PHOSPHATE INJ IP/ USP	50 mg	Vial	
9	D24102C	FULVESTRANT INJ	250 mg	Vial/PFS	
10	D24103C	GEFITINIB TAB IP	250 mg	1 no	
11	D24124C	MELPHALAN TAB IP	5 mg	1 no	
Bid No. 19		M/s. Dr. Reddy's Laboratories Limited, Telangana			
1.	D24066C	CAPECITABINE TAB IP	500 mg	1 no	1. Tendered monograph IP not mentioned in the Product

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
2.	D24188C	DENOSUMAB INJ	120 mg	Vial	<p>Permit and Market Standing Certificate submitted for D24228C - FILGRASTIM INJ IP, 300 mcg, PFS.</p> <p>2. Tendered monograph IP not mentioned in the Import License in Form 10 and Market Standing Certificate submitted for the following D24134C - OXALIPLATIN INJ IP, 100mg Vial D24133C - OXALIPLATIN INJ IP, 50mg Vial.</p> <p>3. Notary attested copy of Valid Market Standing Certificate not submitted for D24232C- CARFILZOMIB INJ 60 mg Vial</p> <p>4. The Product Permit for CARFILZOMIB INJ 30mg Vial is granted on 04.06.2020 for new drugs imported the approval in Form 45 or in Form CT 25 together with the Market Standing Certificate from the date of Manufacturing is to be submitted.</p> <p>5. It is noted that the US-FDA approval submitted for D24231C- CARFILZOMIB INJ 30mg Vial is not Valid.</p> <p>Clarification is to be submitted.</p> <p>6. Notary attested details of 3 batches not furnished in the Performance Statement (Annexure-IV) submitted for D24269C-TRASTUZUMAB INJ, 150 mg, Vial</p>
3.	D24228C	FILGRASTIM INJ IP	300 mcg	PFS	
4.	D24140C	PEGFILGRASTIM INJ	6 mg	Vial/PFS	
5.	D24060C	BEVACIZUMAB INJ	100 mg	Vial	
6.	D24298C	BEVACIZUMAB INJ	400 mg	Vial	
7.	D24231C	CARFILZOMIB INJ	30 mg	Vial	
8.	D24232C	CARFILZOMIB INJ	60 mg	Vial	
9.	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
10.	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
11.	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
12.	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
13.	D24141C	PEMETREXED INJ IP	100 mg	Vial	
14.	D24142C	PEMETREXED INJ IP	500 mg	Vial	
15.	D24145C	RITUXIMAB INJ	100 mg	Vial	
16.	D24146C	RITUXIMAB INJ	500 mg	Vial	
17.	D24156C	TRASTUZUMAB INJ	440 mg	Vial	
18.	D24269C	TRASTUZUMAB INJ	150 mg	Vial	
Bid No. 20		M/s. Emcure Pharmaceuticals Ltd, Pune			

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
1.	D24059C	BENDAMUSTINE INJ IP	100 mg	Vial	<p>1. License no. is wrongly mentioned as L/12/1061/MNB & L/12/1062/MNB instead of L/12/1061/MNB & L/12/1062/MB in the Bid offer form (Annexure II) and Annexure-VIII submitted.</p> <p>2. Notary attested copy of Valid Market Standing Certificate not submitted for the following</p> <p>D24134C - OXALIPLATIN INJ IP, 100mg Vial</p> <p>D24133C - OXALIPLATIN INJ IP, 50mg Vial.</p> <p>D24104C-GEMCITABINE INJ IP, 200mg, Vial</p> <p>D24015C-GEMCITABINE INJ IP, 1gm, Vial</p> <p>3. Notary attested copy of Valid Non Conviction Certificate not submitted for the License no: L/12/1061/MNB & L/12/1062/MB.</p> <p>4. The details of technical persons employed in manufacturing and testing not submitted for M/s. Admac Life Sciences (License no. L/12/1061/MNB & L/12/1062/MB).</p>
2	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
3	D24190C	ERIBULIN INJ	0.44 mg/ml	2ml Vial	
4	D24294C	FERRIC CARBOXYMALTOSE INJ	1gm/ 20 ml	Vial	
5	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
6	D24105C	GEMCITABINE INJ IP	1gm	Vial	
7	D24133C	OXALIPLATIN INJ IP	50 mg	Vial	
8	D24134C	OXALIPLATIN INJ IP	100 mg	Vial	
Bid No. 21		M/s. Genova Biopharmaceuticals Ltd., Maharashtra			
1.	D24228C	FILGRASTIM INJ IP	300 Mcg	PFS	Submitted the required documents.
2	D24140C	PEGFILGRASTIM INJ	6mg	Vial/PFS	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
Bid No. 22		M/s. Getwell Pharma India Private Limited, Haryana.			
1.	D24059C	BENDAMUSTINE INJ IP	100 mg	Vial	<p>1. Annual Turn Over Statement submitted is not attested by Notary Public.</p> <p>2. It is noted that fresh license is issued to the firm on 01.04.2023 after change in constitution. Hence previous manufacturing license in before change in constitution is to be submitted.</p> <p>3. Notary attested copy of Product Permit and Performance statement in Annexure-IV not submitted for the following</p> <p>D24064C-LEUCOVORIN CALCIUM INJ IP 15 mg Amp</p> <p>D24065C-LEUCOVORIN CALCIUM INJ IP 50 mg Vial</p> <p>4. Notary attested copy of Valid Market Standing Certificate not submitted for any of the quoted items.</p>
2.	D24063C	BORTEZOMIB INJ IP	2 mg	Vial	
3	D24091C	DOXORUBICIN (PEGYLATED LIPOSOMAL) INJ	50 mg	Vial	
4	D24090C	DOXORUBICIN LIPOSOMAL INJ	20 mg	Vial	
5	D24097C	ETOPOSIDE INJ IP	100 mg	Vial	
6	D24102C	FULVESTRANT INJ	250 mg	Vial/ PFS	
7	D24117C	L ASPARAGINASE INJ	5000 iu	Vial	
8	D24125C	MESNA INJ	200 mg	Amp	
9	D24144C	PROTEIN BOUND PACLITAXEL INJ	100 mg	Vial	
10	D24185C	DECITABINE INJ	50 mg	Vial	
11	D24082C	DOCETAXEL INJ IP	20 mg	Vial	
12	D24083C	DOCETAXEL INJ IP	80 mg	Vial	
13	D24084C	DOCETAXEL INJ IP	120 mg	Vial	
14	D24104C	GEMCITABINE INJ IP	200 mg	Vial	
15	D24105C	GEMCITABINE INJ IP	1 gm	Vial	
16	D24115C	IRINOTECAN INJ IP	40 mg	Vial	
17	D24116C	IRINOTECAN INJ IP	100 mg	Vial	
18	D24064C	LEUCOVORIN CALCIUM INJ IP	15 mg	Amp	
19	D24065C	LEUCOVORIN CALCIUM INJ IP	50 mg	Vial	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
20	D24136C	PACLITAXEL INJ IP	30 mg	Vial	
21	D24137C	PACLITAXEL INJ IP WITH CODON SET	100 mg	Vial	
22	D24138C	PACLITAXEL INJ IP WITH CODON SET	260 mg	Vial	
23	D24141C	PEMETREXED INJ IP	100 mg	Vial	
24	D24142C	PEMETREXED INJ IP	500 mg	Vial	

Sd/-
MANAGING DIRECTOR
KERALA MEDICAL SERVICES CORPORATION LTD.
(TENDER INVITING AUTHORITY)